{"groups":[{"description":"Idelalisib (Zydelig®) 150 mg tablet twice daily + bendamustine intravenously (starting dose of 90 mg/m\\^2 for up to 6 total cycles) + rituximab (375 mg/m\\^2 on Day 1 and 500 mg/m\\^2 thereafter for at total of 6 infusions)","id":"FG000","title":"Idelalisib+Bendamustine+Rituximab"},{"description":"Placebo tablet twice daily + bendamustine intravenously (starting dose of 90 mg/m\\^2 for up to 6 total cycles) + rituximab intravenously (375 mg/m\\^2 on Day 1 and 500 mg/m\\^2 thereafter for at total of 6 infusions)","id":"FG001","title":"Placebo+Bendamustine+Rituximab"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"116"},{"groupId":"FG001","numSubjects":"122"}],"type":"Study Terminated by Sponsor"},{"reasons":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"6"}],"type":"Withdrew Consent"},{"reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"3"}],"type":"Investigator's Discretion"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"}],"type":"Non-Compliance with Study Drug"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"157"},{"groupId":"FG001","numSubjects":"154"}],"type":"STARTED"},{"achievements":[{"comment":"Completed = reached primary efficacy endpoint of progressive disease or death.","groupId":"FG000","numSubjects":"13"},{"comment":"Completed = reached primary efficacy endpoint of progressive disease or death.","groupId":"FG001","numSubjects":"21"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"144"},{"groupId":"FG001","numSubjects":"133"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"392 participants were screened.","recruitmentDetails":"Participants were enrolled at study sites in the North America, Australia, and Europe. The first participant was screened on 05 February 2014. The last study visit occurred on 16 June 2016."}